Cat. No. 1570
Alternative Name: CBD
Chemical Name: 2-[(1R,6R)-3-Methyl-6-(1-methylethe
Biological ActivityNon-psychotropic constituent of cannabis that is anticonvulsive, antihyperalgesic and neuroprotective in vivo. GPR55 and weak CB1 antagonist (IC50 values are 0.445 and 3.35 μM), CB2 receptor inverse agonist and inhibitor of anandamide uptake (IC50 = 27.5 μM). Also a weak agonist at VR1 vanilloid receptors (EC50 = 3.5 μM).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Ryberg et al (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br.J.Pharmacol. 152 1092. PMID: 17876302.
Thomas et al (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br.J.Pharmacol. 150 613. PMID: 17245363.
Costa et al (2004) Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br.J.Pharmacol. 143 247. PMID: 15313881.
Petitet et al (1998) Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci. 63 PL1. PMID: 9667767.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses (-)-Cannabidiol from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: (-)-Cannabidiol, supplier, Natural, cannabinoids, AMT, inhibitors, inhibits, GPR55, antagonists, weak, CB1, CB2, inverse, agonists, Anandamide, Transporters, Monoamine, Neurotransmitter, Non-Selective, Receptors, cb2r, cb1r, Tocris Bioscience, Non-selective Cannabinoid Antagonist products